Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Elaine M Hay a Staffordshire Rheumatology Centre, The
Haywood, Burslem, Stoke on Trent ST6 7AG, b Primary Care Sciences
Research Centre, Keele University School of Postgraduate Medicine,
Hartshill, Stoke on Trent ST4 7QB, c 1980 Great Western Road, Glasgow G13 2SW
Correspondence to: E M Hay Pra19{at}keele.ac.uk
| |
Abstract |
|---|
|
|
|---|
Objective:
To compare the clinical effectiveness of
local corticosteroid injection, standard non-steroidal
anti-inflammatory drugs, and simple analgesics for the early treatment
of lateral epicondylitis in primary care.
Design:
Multicentre pragmatic randomised controlled trial.
Setting:
23 general practices in North Staffordshire and South Cheshire.
Participants:
164 patients aged 18-70 years presenting
with a new episode of lateral epicondylitis.
Interventions:
Local injection of 20 mg
methylprednisolone plus lignocaine, naproxen 500 mg twice daily for two
weeks, or placebo tablets. All participants received a standard advice
sheet and co-codamol as required.
Main outcome measures:
Participants' global
assessment of improvement (five point scale) at four weeks. Pain,
function, and "main complaint" measured on 10 point Likert scales
at 4 weeks, 6 months, and 12 months.
Results:
Over 2 years, 53 subjects were
randomised to injection, 53 to naproxen, and 58 to placebo. Prognostic
variables were similar between groups at baseline. At 4 weeks, 48 patients (92%) in the injection group were completely better or
improved compared with 30 (57%) in the naproxen group (P<0.001) and
28 (50%) in the placebo group (P<0.001). At 12 months, 43 patients (84%) in the injection group had pain scores
3 compared with 45 (85%) in the naproxen group and 44 (82%) in the placebo group (P>0.05).
Conclusions:
Early local corticosteroid injection is
effective for lateral epicondylitis. Outcome at one year was good in
all groups, and effective early treatment does not seem to influence this.
|
Key messages
|
| |
Introduction |
|---|
|
|
|---|
Lateral epicondylitis (tennis elbow) is a painful condition that affects about 4 adults per 1000 annually.1 Most cases are managed in primary care, and more than 40 possible treatments have been proposed,2 reflecting a lack of consensus about optimal management. General practitioners commonly use non-steroidal anti-inflammatory drugs to treat tennis elbow, but there are no trials comparing them with painkillers and one study found no clinically important benefit over placebo.3 Two reviews of corticosteroid injections concluded that there was insufficient evidence to support their use in treating tennis elbow, but the methodological quality of most trials was poor. 4 5 Only two primary care studies were identified, both with methodological shortcomings, including small sample sizes. One, in an occupational health centre, showed no difference between injection, indomethacin, and a wrist brace over 12 months.6 The second, conducted in an army clinic, found no difference between ultrasound, transcutaneous nerve stimulation, and local injection five days after intervention.7
We conducted a large pragmatic randomised trial comparing three
conventional treatments for lateral epicondylitis in primary care. The
aims of the study were to determine whether local corticosteroid injection, a two week course of naproxen, or simple analgesia provides
the best short term treatment for new episodes and which of these
treatments provides best long term relief of symptoms.
| |
Methods |
|---|
|
|
|---|
Study design
The study was a multicentre, pragmatic randomised trial in primary care. We recruited consecutive patients aged 18-70 years who consulted their general practitioner with a new episode of
lateral epicondylitis (pain and tenderness in the lateral region of the
elbow and no consultation with symptoms in the same elbow during the
preceding 12 months) during November 1995 to December 1997. Exclusion
criteria were a history of inflammatory arthritis or gross structural
abnormality of the elbow; contraindications to non-steroidal
anti-inflammatories or local steroid injection; and pregnancy or breast
feeding. The trial was explained to patients by their general
practitioner, who gave participants an information leaflet and faxed a
registration form to the research centre. Baseline assessments were
performed by a study nurse (usually in the patients' homes) within two
working days of registration. Written informed consent was obtained,
and the study was approved by the local research ethics committees
of North Staffordshire and South Cheshire.
Randomisation
Treatment allocation was according to the study number
given to the patient at the baseline assessment. Numbers were issued in
a predetermined random sequence in blocks of six by general practice
and generated with a random number table. The number corresponded with
that on identical treatment packs kept in the general practitioners' surgeries.
Treatment protocols
Patients returned to their general practitioner after the
baseline assessment to receive one of three treatments.
Patients were given a local
corticosteroid injection of methylprednisolone 20 mg and 0.5 ml 1%
lignocaine according to a standard technique. The injection was
performed with the patient's arm resting flexed on a firm surface. The
methylprednisolone and lignocaine were drawn up in separate syringes.
After the skin was cleaned, lignocaine was injected deep into the
subcutaneous tissues and muscles 1 cm distal to the lateral epicondyle
and aiming towards the tender spot. The syringes were then exchanged and methylprednisolone injected radially. The needle was withdrawn cleanly and firm pressure applied.
Naproxen group
Patients were prescribed enteric
coated naproxen 500 mg twice daily for two weeks. Standard advice was given to take the drug with food and about potential side effects.
Placebo group
Patients were give placebo tablets
(unmarked vitamin C) twice daily for two weeks. Standard advice was given as for the naproxen group.
Participants were provided with co-codamol for additional pain relief
and an information leaflet about "tennis elbow" based on the
Arthritis Research Campaign publication but omitting specific treatment recommendations.
Outcome measures
Outcome assessments were performed by a blinded study nurse
before randomisation and at four weeks, six months, and 12 months. The
baseline assessment also included demographic variables, medical
history, and potential prognostic variables. Case notes were reviewed
after completion of follow up.
Analysis
Sample size calculations were based on publications which
describe a 70% recovery or improvement with non-steroidal anti-inflammatory drugs after four weeks (two tailed
=0.05,
=0.2).10 Overall success was defined a priori as a 20%
difference between treatment groups in the primary outcome measure. A
total sample size of 180 patients was required.
=0.05. We compared groups with
2 test for nominal variables or Fisher's
exact test where appropriate for small samples. Ordinal variables were
compared by Mann-Whitney U tests. Area under the curve slopes were
compared by the methods of Matthews et al.11 Analyses were
carried out with SPSS version 8.0.
| |
Results |
|---|
|
|
|---|
Thirty seven general practitioners from 23 practices registered 182 patients. Of these patients, 164 (78 women) were randomised: 53 to receive local injection, 53 to naproxen, and 58 to placebo. Eleven of the 37 general practitioners recruited six or more patients, accounting for 94 (57%) of the 164 in the study population (overall range recruited 1-17). Allocation of intervention and baseline patient characteristics were similar in high recruiting and low recruiting practices. The figure shows the progress of patients through the trial, and table 1 shows the baseline characteristics of the study sample.
|
|
At four weeks, outcome in the injection group was significantly better than in the naproxen and placebo groups (table 2). Naproxen showed no advantage over placebo. Recovery or improvement was reported in 48 patients (92%) in the injection group, 30 patients (57%) in the naproxen group, and 28 patients (50%) in the placebo group.
|
Table 3 shows median scores for the Likert scales for pain, function, and "main complaint" at each follow up assessment. At four weeks, injection showed a clear advantage over naproxen and placebo. There were some small but significant differences in favour of naproxen or placebo at 6 and 12 months.
|
The clinical interpretation of these differences was explored as
follows. Comparison between the Likert scores for pain and participants' global assessment of change at four weeks showed that
89% of subjects scoring
3 rated themselves as completely better or
improved; none had got worse. Based on this, outcome was dichotomised
as "better" (pain score
3) or "not better" (pain score
4). This allowed us to compare the numbers of patients who had
responded to treatment at each time point (table 4). Overall, 84% of
recruited patients were better at 12 months, and this proportion was
similar for each treatment group (injection 84%, naproxen 85%,
placebo 82%). Some subjects in the injection group, however, had
worsened at six months but improved again by 12 months.
|
Details of the self reported presence of elbow pain, the nurse's examination findings, and disability scores are given on the BMJ's website. Injection was superior to naproxen and placebo at four weeks; the three groups were similar at 12 months with a relapse in some patients in the injection group at six months.
The numbers of patients taking time off paid employment at four weeks were five (14%) in the injection group, four (10%) in the naproxen group, and eight (17%) in the placebo group; the numbers at 12 months were five (14%), four (10%), and 10 (21%), respectively (P>0.05 for both times). The numbers of patients taking painkillers in each group at four weeks and six and 12 months were similar: 18 (35%), 22 (42%), and 29 (50%) at four weeks; 21 (40%), 19 (36%), 23 (40%) at six months, and 14 (26%), 14 (26%), and 16 (28%) at 12 months for injection, naproxen, and placebo groups respectively.
Co-interventions
Case notes were available for 160 participants; four had
transferred practices. In all, 155 records (50 injection, 52 naproxen,
53 placebo) had information about the randomised treatment, and 151 records (49 injection, 50 naproxen, 52 placebo) had complete
information concerning patient treatment between the date of referral
and follow up.
|
Side effects
Local skin atrophy at the lateral epicondyle was observed
in only two patients at six months and one patient at 12 months. The
three affected patients were from the naproxen and placebo groups, and
only one had additionally received a local injection. Naproxen was
discontinued in four patients because of gastrointestinal side effects.
One patient on naproxen had an allergic reaction characterised by
oedema. Pain diaries recorded for five days after intervention showed a
minor, non-significant, increase in severity of pain after injection,
lasting one day only.
| |
Discussion |
|---|
|
|
|---|
Our results have two important implications for the management of new episodes of lateral epicondylitis in general practice. Firstly, a local corticosteroid injection is an effective, safe initial treatment with a clear clinical advantage four weeks later compared with a two week course of naproxen. Naproxen had no advantage over simple analgesics and a standard advice sheet alone. Secondly, by 12 months most patients with lateral epicondylitis had improved irrespective of initial treatment. Early effective treatment with local steroid injection resulted in more rapid resolution of symptoms but did not influence long term outcome.
A small proportion of patients failed to respond to the initial injection, and some patients who had initially improved had worse symptoms at six months. These may be patients whose primary disease lay within the cervical spine or whose local injection was not accurately placed. We did not give participants specific instructions about resting or abstaining from work or sporting activities, and effective pain relief might have led to a premature return to activity in the injection group causing a temporary worsening of their symptoms. Studies of other painful musculoskeletal syndromes, such as low back pain,12 have observed similar lack of association between early response to treatment and longer term outcomes. Further research is required to investigate these issues.
Strengths and weaknesses
The main criticism of previous reviews of treatment for
tennis elbow has been the lack of methodologically rigorous
trials.
4 5
Our pragmatic study, carried out in a routine
primary care setting, included a relatively homogeneous population of
patients and was sufficiently large to detect clinically important
differences between treatment groups. Possible prognostic variables
were equally distributed between the three treatment groups at
baseline. Although patients and doctors knew which treatment was given,
the nurse who assessed outcome remained unaware of the treatment
allocation throughout. Home based assessment minimised loss to follow
up, enabling us to perform a robust intention to treat analysis.
Conclusions
We conclude that corticosteroid injections are the initial
treatment of choice for lateral epicondylitis in primary care if the
objective of treatment is to obtain optimal relief of symptoms during
the early weeks. Patients, however, can be reassured that regardless of
their treatment the probability is high that they will get better in
the longer term. Further research should determine why some patients do
less well after initial pain relief by injection.
| |
Acknowledgments |
|---|
We thank the general practitioners from the Community Musculoskeletal Research Group (see BMJ's website for list of names) for their enthusiasm and hard work. We thank the Primary Care Rheumatology Society, Professor A Silman, and Dr P Brennan for help with the study design and early encouragement and endorsement; Gill Latham for providing holiday cover for the study nurse; and Bronwyn Montgomory for preparing the treatment packages. Finally we thank the patients who made this project possible.
Contributors: EMH reviewed the literature, prepared the grant application, contributed to the design of the study, coordinated the study, contributed to the analysis, and acts as guarantor. SMP contributed to the literature review, designed the questionnaires, performed the patient interviews, contributed to coordination of the study, and performed most of the data entry. ML had the main responsibility for data analysis and contributed to the design and running of the study. GH contributed to the design of the study. PC contributed to the design and coordination of the study and supervised the data analysis. EMH wrote the manuscript, and tables and figures were prepared by ML. Various drafts were reviewed and revised by all the authors.
| |
Footnotes |
|---|
Funding: Arthritis Research Campaign. Methylprednisolone injections were provided by UpJohn and enteric coated naproxen by Syntex.
Competing interests: None declared.
website extra: A further table and members of the the Community Musculoskeletal Research Group are given on the BMJ's website www.bmj.com
| |
References |
|---|
|
|
|---|
| 1. | Hamilton PG. The prevalence of humeral epicondylitis: a survey in general practice. J R Coll Gen Pract 1986; 36: 464-465[Medline]. |
| 2. |
Chard MD, Hazleman BL.
Tennis elbow a reappraisal.
Br J Rheumatol
1989;
28:
186-190 |
| 3. |
Labelle H, Guibert R.
Efficacy of diclofenac in lateral epicondylitis of the elbow also treated with immobilization. University of Montreal Orthopaedic Research Group.
Arch Fam Med
1997;
6:
257-262 |
| 4. | Labelle H, Guibert R, Joncas J, Newman N, Fallaha M, Rivard CH. Lack of scientific evidence for the treatment of lateral epicondylitis of the elbow. An attempted meta-analysis. J Bone Joint Surg [Br] 1992; 74B: 646-651. |
| 5. | Assendelft WJ, Hay EM, Adshead R, Bouter LM. Corticosteroid injections for lateral epicondylitis: a systematic overview. Br J Gen Pract 1996; 46: 209-216[Medline]. |
| 6. | Kivi P. The etiology and conservative treatment of humeral epicondylitis. Scand J Rehabil Med 1983; 15: 37-41[Medline]. |
| 7. | Halle JS, Franklin RJ, Karalfa BL. Comparison of four treatment approaches for lateral epicondylitis of the elbow. J Orthop Sports Phys Ther 1986; 8: 62-69[Medline]. |
| 8. | Beurskens AJ, de Vet HC, Lindeman E, Koke AJ, Regtop W, van der Hiejden GJ, et al. Efficacy of traction for non-specific low back pain: 5 week results of a randomised controlled trial. Lancet 1995; 346: 1596-1600[Medline]. |
| 9. | Stratford P, Levy DR, Gauldie S, Levy K, Miseferi D. Extensor carpi radialis tendonitis: a validation of selected outcome measures. Physiotherapy Canada 1987; 39: 250-255. |
| 10. | Stull PA, Jokl P. Comparison of diflusinal and naproxen in the treatment of tennis elbow. Clin Ther 1986; 9: 62-66. |
| 11. | Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235. |
| 12. | Mitchell RI, Carmen GM. Results of a multicenter trial using an intensive active exercise programme for the treatment of acute soft tissue and back injuries. Spine 1990; 15: 514-521[Medline]. |
| 13. |
Lanyon P, Pope D, Croft P.
Rheumatology education and management skills in general practice: a national study of trainees.
Ann Rheum Dis
1995;
54:
735-739 |
| 14. |
Foy R, Parry J, McAvoy B.
Clinical trials in primary care: targeted payments for trials might help improve recruitment and quality.
BMJ
1998;
317:
1168-1169 |
(Accepted 29 July 1999)
Read all Rapid Responses